

For lots with total weight greater than 150,000 pounds, a sample will be selected from 20 percent of the containers in the lot and consist of 25 lb of shelled nuts or 50 lb of in-shell nuts for each multiple of 75,000 lb (e.g., 150,000 to 225,000 lb requires a 3-fold sample of 75 lb shelled or 150 lb of in-shell nuts).

2. Perform aflatoxin assay.

(a) In-Shell Lots.

The entire sample of shells and kernels will be ground in a vertical cutter mixer. A well-mixed portion of the ground composite will be assayed chemically for total aflatoxins, using either of the two methods for aflatoxin assay in pistachios described in the book of Official Methods of Analysis of AOAC International, 16th ed., Vol. II, Sec. 49.2.23. The aflatoxin level will be calculated on a kernel weight basis.

(b) Shelled Lots

The entire sample shall be ground, including those kernels which have an obvious inedible appearance. A well-mixed portion of the ground composite will be assayed as in paragraph 2.(a) above.

3. Report Results

(a) A separate analysis certificate will be issued for each lot. Appropriate identification marks will be shown on each certificate so that the report can be related to the specific lot sampled.

(b) Provide appropriate FDA District Office the results of aflatoxin analysis for lots that may be subject to action under the Food, Drug, and Cosmetic Act and analysis certificate on any lot upon request.

FDA intends to:

1. Notify AMS of the criteria FDA will use concerning total aflatoxins levels in lots to determine whether they may be subject to action under the Food, Drug, and Cosmetic Act.
2. Review results of aflatoxin analysis for lots provided by AMS to determine whether they may be subject to action under the Food, Drug, and Cosmetic Act.

AMS and FDA mutually agree to:

1. Designate a person to serve as a central contact to whom communications dealing with this agreement or matters affected thereby may be first referred for attention.

For the Food and Drug Administration: Director, Division of Programs and Enforcement Policy, HFS-305 (currently Terry C. Troxell, Ph.D.) Office of Plant and Dairy Foods and Beverages, Center for Food Safety and Applied Nutrition 200 C. Street S.W. Washington, D.C. 20204 Telephone: 202-205-5321

For the Agricultural Marketing Service: Director, Science and Technology Division (currently William J. Franks, Jr.) USDA, AMS 14th & Independence Avenue, S.W. Washington, D.C. 20090-6456, Telephone: 202-720-6496.

2. Maintain close working relations with each other, both in headquarters as well as in the field.
3. Work with industry toward greater efficiency in connection with improvement of the testing program.

BASIS OF COOPERATION—This Memorandum of Understanding defines in

general terms the basis on which the parties concerned will cooperate, and does not constitute a financial obligation to serve as a basis for expenditures. Each party will handle and expend its own funds. Any and all expenditures from Federal funds in the Department of Agriculture made in conformity with the plans outlined in the Memorandum of Understanding must be in accord with Department rules and regulations and in each instance based upon appropriate finance papers. Expenditures made by FDA will be in accord with its rules and regulations.

Nothing in this agreement modifies other existing agreements, nor does it preclude entering into separate agreements setting forth procedures for special programs that can be handled more efficiently and expeditiously by such special agreement.

The responsibilities assumed by the cooperating parties under this Memorandum of Understanding are contingent upon funds being available from which expenditures legally may be made.

DURATION—This agreement will continue in force indefinitely. It may be amended or terminated by mutual consent of the parties in writing. It may be terminated by either party upon 30 days' notice in writing to the other party.

This agreement is hereby approved for the Agricultural Marketing Service. Done at Washington, D.C. on October 1, 1997, Barbara A. Chaffey,

Deputy Administrator, Marketing Programs
Agricultural Marketing Service.

This agreement is hereby approved for the Food and Drug Administration: Done at Washington, D.C. on October 1, 1997, Ronald G. Chesemore, Associate Commissioner for Regulatory Affairs.

[FR Doc. 97-31809 Filed 12-4-97; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 96N-0496]

Agency Information Collection Activities; Announcement of OMB Approval

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Reporting and Recordkeeping Requirements for Manufacturers and Distributors of Electronic Products" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).

FOR FURTHER INFORMATION CONTACT: Margaret R. Schlosburg, Office of

Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of August 28, 1997 (62 FR 45665), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under section 3507 of the PRA (44 U.S.C. 3507). An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0025. The approval expires on October 31, 2000.

Dated: November 27, 1997.

William K. Hubbard,

Associate Commissioner for Policy
Coordination.

[FR Doc. 97-31943 Filed 12-4-97; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Heart, Lung, and Blood Institute Special Emphasis Panel (SEP) meetings:

Name of SEP: Coronary Stent Angioplasty: Factors Affecting Restenosis (Telephone Conference Call).

Date: January 6, 1998.

Time: 9:00 a.m.

Place: 6701 Rockledge Drive, Room 7214, Bethesda, Maryland 20892.

Contact Person: C. James Scheirer, Ph.D., Two Rockledge Center, Room 7220, 6701 Rockledge Drive, Bethesda, MD 20892-7924, (301) 435-0266.

Purpose/Agenda: To review and evaluate grant applications.

Name of SEP: Specialized Centers of Research in Acute Lung Injury.

Date: January 7-8, 1998.

Time: 8:00 a.m.

Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, Maryland 20815.

Contact Person: Anne P. Clark, Ph.D., Two Rockledge Center, Room 7186, 6701 Rockledge Drive, Bethesda, MD 20892-7924, (301) 435-0280.

Purpose/Agenda: To review and evaluate grant applications.

Name of SEP: Specialized Centers of Research in Neurobiology of Sleep and Sleep Apnea.